Sartorius Stedim BiotechSRTOY -1.06%82 PEG Ratio is 58.28 as of Jul. 02, 2026, which is 5198% above its 10-year median of 1.10. GuruFocus rates SRTOY with a GF Score™ of 82/100 and a GF Value™ of $23.87 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 207 Medical Devices & Instruments companies, Sartorius Stedim Biotech ranks worse than 99.03% on this metric.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Sartorius Stedim Biotech's PEG Ratio or its related term are showing as below:
SRTOY'
s PEG Ratio Range Over the Past 10 Years
Min: 0.41 Med: 1.1 Max: 59.02
Current: 58.28
During the past 13 years, Sartorius Stedim Biotech's highest PEG Ratio was 59.02. The lowest was 0.41. And the median was 1.10.
SRTOY's PEG Ratio is ranked worse than 99.03% of 207
companies
in the Medical Devices & Instruments industry
Industry Median: 2.03
vs SRTOY: 58.28
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Sartorius Stedim Biotech (OTCPK:SRTOY) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Sartorius Stedim Biotech PEG Ratio Related Terms
Sartorius Stedim Biotech PEG Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Sartorius Stedim Biotech's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sartorius Stedim Biotech PEG Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sartorius Stedim Biotech's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Sartorius Stedim Biotech's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Sartorius Stedim Biotech (SRTOY) has a PEG Ratio of 58.28 as of Jul. 02, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Sartorius Stedim Biotech and its competitors. This is 5198% above median its historical median of 1.10. Over the past decade, Sartorius Stedim Biotech's PEG Ratio has ranged from 0.41 to 59.02. According to the industry distribution chart, Sartorius Stedim Biotech ranks #205 out of 207 companies in the Medical Devices & Instruments industry, placing it in the top 99%.
Is Sartorius Stedim Biotech's PEG Ratio too high?
Sartorius Stedim Biotech's current PEG Ratio of 58.28 is 5198% above median its 10-year median of 1.10. Over the past 10 years, this metric has ranged from a low of 0.41 to a high of 59.02. The Medical Devices & Instruments industry median PEG Ratio is 2.03. Sartorius Stedim Biotech's value of 58.28 is 2770.9% above this industry median. Based on the distribution chart, Sartorius Stedim Biotech ranks #205 out of 207 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Sartorius Stedim Biotech has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sartorius Stedim Biotech's PEG Ratio compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Sartorius Stedim Biotech ranks #205 out of 207 companies for PEG Ratio. This places Sartorius Stedim Biotech in the lower half of its industry. The industry median PEG Ratio is 2.03. Sartorius Stedim Biotech's value of 58.28 is 2770.9% above this benchmark. Historically, Sartorius Stedim Biotech's own PEG Ratio has ranged from 0.41 to 59.02 over the past decade. While the company's 10-year median is 1.10 vs. the industry median of 2.03, Sartorius Stedim Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Medical Devices & Instruments company?
The median PEG Ratio among Medical Devices & Instruments companies is 2.03, based on 207 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sartorius Stedim Biotech's current PEG Ratio of 58.28 is 2770.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Sartorius Stedim Biotech and its competitors. For the Medical Devices & Instruments industry, the median PEG Ratio is 2.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sartorius Stedim Biotech's current PEG Ratio is 58.28, which is 5198% above median its own 10-year median of 1.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sartorius Stedim Biotech stock overvalued right now?
Based on GuruFocus' analysis, Sartorius Stedim Biotech (SRTOY) is currently considered Modestly Undervalued. The stock's GF Value™ is $23.87, compared to a current price of $20.45 — trading 14.3% below its estimated fair value. The current PEG Ratio is 58.28, which is 5198% above median its 10-year median of 1.10 and 2770.9% above the Medical Devices & Instruments industry median of 2.03. Sartorius Stedim Biotech's overall GF Score™ is 82/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Sartorius Stedim Biotech (SRTOY), the current PEG Ratio is 58.28 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sartorius Stedim Biotech (SRTOY) Overvalued in 2026?
Based on GuruFocus' analysis, Sartorius Stedim Biotech stock appears to be undervalued.
The current stock price of $20.45 is trading 14.3% below its estimated GF Value™ of $23.87.
GuruFocus considers Sartorius Stedim Biotech to be Modestly Undervalued.
Key valuation signals for SRTOY:
PEG Ratio: 58.28 (5198% above median its 10-year median of 1.10)
GF Value™: $23.87 vs. price of $20.45 (14.3% below fair value)
Industry Position: 2770.9% above the Medical Devices & Instruments median (#205 of 207)
No single metric tells the full story. See the SRTOY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sartorius Stedim Biotech is a leading provider of bioprocessing solutions. It sells equipment and consumables for fermentation, filtration, fluid management, purification, and cell culture media for manufacturing biologic drugs and has a focus on single-use technology. It is a subsidiary of Sartorius AG, which has 71.5% ownership and 83% voting control. The business is geographically diverse, with 35% of sales from the Americas, 42% from Europe, the Middle East, and Africa, 15% from Asia excluding China, and 8% from China.
82GF Score
Get the complete analysis for SRTOY
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SRTOY has been successfully added to your 
